Comparison of right-to-left shunt characteristics in cryptogenic embolic ischemic stroke and non-cardioembolic ischemic stroke

Abstract

Background: Patent foramen ovale (PFO) has been considered a potential mechanism of embolic stroke of undetermined origin. Objective: The aim of the present study was to identify the features of the right-to-left shunt (RLS) in patients with undetermined embolic ischemic stroke and compare them with those of patients with non-cardioembolic ischemic stroke. Methods: A retrospective study was conducted with 168 patients with stroke and RLS separated into the following two groups: the undetermined embolic stroke group (UES group) and non-cardioembolic stroke group (NCES group). All patients were assessed by transcranial Doppler to evaluate the presence and quantification of microembolic signals (MES) at rest and under Valsalva maneuver. Results: Of all patients evaluated in the current study, 96 were included in the UES group and 72 in the NCES group. In the UES group, 65 patients had RLS with ≥10 MES (67.7%), which was higher than that observed in the NCES group (51.4%, p=0.038). According to the moment of the cardiac cycle, 75 patients (78.1%) in the UES group had a positive test at rest compared to 42 (58.3%) in the NCES group (p=0.007). Conclusions: The current study demonstrated that almost 70% of patients with undetermined embolic stroke and PFO presented a large RLS and more than 75% had RLS at rest. These findings suggest that the size of the shunt should be taken into account when evaluating whether PFO could be a possible mechanism underlying cryptogenic stroke.

RESUMO

Antecedentes: Uma das potenciais fontes embólicas no acidente vascular cerebral (AVC) de origem indeterminada é o forame oval patente (FOP). Objetivo: O objetivo do presente estudo foi identificar as características do shunt direita-esquerda em paciente com AVC de etiologia indeterminada, presumidamente embólica, e comparar tais características com pacientes apresentando AVC por outras causas não embólicas. Métodos: Trata-se de um estudo retrospectivo com 168 pacientes com AVC e forame oval patente, separados em dois grupos: AVC embólico de etiologia indeterminada e AVC por outras causas não embólicas. Todos os pacientes foram submetidos a Doppler transcraniano, para avaliar a presença de shunt direita-esquerda por meio do teste de embolia paradoxal. Além da quantificação de microbolhas, também foi avaliada a presença de shunt em repouso e sob manobra de Valsalva. Resultado: Do total, 96 pacientes foram incluídos no primeiro grupo (AVC indeterminado) e 72, no segundo grupo (AVC não embólico). No primeiro grupo, 65 pacientes exibiram shunt com passagem de mais de 10 microbolhas (67,5%), enquanto no segundo grupo isso aconteceu em 51,4% (p=0,038) dos casos. Além disso, 75 pacientes (78,1%) do primeiro grupo tiveram teste positivo ao repouso, comparados com 42 pacientes (58,3%) no segundo grupo (p=0,007). Conclusão: O presente estudo demonstrou que até 70% dos pacientes com AVC de etiologia indeterminada e forame oval apresentaram shunts maiores; em mais de 75%, houve passagem de microbolhas ao repouso. Esses achados sugerem que as características do shunt, como quantidade de microbolhas e passagem ao repouso, devem ser levadas em consideração na avaliação do FOP como possível mecanismo subjacente ao AVC.

Keywords:

Foramen Ovale, Patent - Embolism, Paradoxical - Ultrasonography, Doppler, Transcranial - Stroke - Ischemic Stroke

Palavras-chave:

Forame Oval Patente - Embolia Paradoxal - Ultrassonografia Doppler Transcraniana - Acidente Vascular Cerebral - AVC Isquêmico

• References

• 1 Ntaios G, Papavasileiou V, Milionis H, Makaritsis K, Manios E, Spengos K, et al. Embolic strokes of undetermined source in the athens stroke registry: a descriptive analysis. Stroke. 2015 Jan;46(1):176-81. https://doi.org/10.1161/STROKEAHA.114.007240
• 2 Desai AJ, Fuller CJ, Jesurum JT, Reisman M. Patent foramen ovale and cerebrovascular disease. Nat Clin Pract Cardiovasc Med. 2006 Aug;3(8):446-55. https://doi.org/10.1038/ncpcardio0597
• 3 Meissner I, Khandheria BK, Heit JA, Petty GW, Sheps SG, Schwartz GL, et al. Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. J Am Coll Cardiol. 2006 Jan;47(2):440-5. https://doi.org/10.1016/j.jacc.2005.10.044
• 4 Di Tullio M, Sacco R, Gopal A, Mohr JP, Homma S. Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Intern Med. 1992 Sep;117(6):461-5. https://doi.org/10.7326/0003-4819-117-6-461
• 5 Bang OY, Lee MJ, Ryoo S, Kim SJ, Kim JW. Patent foramen ovale and stroke–current status. J Stroke. 2015 Sep;17(3):229-37. https://doi.org/10.5853/jos.2015.17.3.229
• 6 Webster MWI, Smith HJ, Sharpe DN, Chancellor AM, Swift DL, Bass NM, et al. Patent foramen ovale in young stroke patients. Lancet. 1988 Jul;332(8601):11-2. https://doi.org/10.1016/S0140-6736(88)92944-3
• 7 Cabanes L, Mas JL, Cohen A, Amarenco P, Cabanes PA, Oubary P, et al. Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age. A study using transesophageal echocardiography. Stroke. 1993 Dec;24(12):1865-73. https://doi.org/10.1161/01.str.24.12.1865
• 8 Mas J-L, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017 Sep;377(11):1011-21. https://doi.org/10.1056/NEJMoa1705915
• 9 Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017 Sep; 377:1022-32. https://doi.org/10.1056/NEJMoa1610057
• 10 Søndergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017 Sep;377:1033-42. https://doi.org/10.1056/NEJMoa1707404
• 11 Lange MC, Zétola VF, Souza AM, Novak FM, Piovesan EJ, Werneck LC. Intracranial embolism characteristics in PFO patients: A comparison between positive and negative PFO by transesophageal echocardiography: the rule of the nine. J Neurol Sci. 2010 Jun;293(1-2):106-9. https://doi.org/10.1016/j.jns.2010.02.003
• 12 González-Alujas T, Evangelista A, Santamarina E, Rubiera M, Gómez-Boscha Z, Rodríguez-Palomares JF, et al. Diagnóstico y cuantificación del foramen oval permeable. ¿Cuál es la técnica de referencia? Estudio simultáneo con Doppler transcraneal, ecocardiografía transtorácica y transesofágica. Rev Esp Cardiol. 2011 Feb;64(2):133-9. https://doi.org/10.1016/j.recesp.2010.10.009
• 13 Tobe J, Bogiatzi C, Munoz C, Tamayo A, Spence JD. Transcranial Doppler is complementary to echocardiography for detection and risk stratification of patent foramen ovale. Can J Cardiol. 2016 Aug;32(8):986.e9-986.e16. https://doi.org/10.1016/j.cjca.2015.12.009
• 14 Hart RG, Diener H-C, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014 Apr;13(4):429-38. https://doi.org/10.1016/S1474-4422(13)70310-7
• 15 Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Wolf ME, Hennerici MG. The ASCOD Phenotyping of Ischemic Stroke (Updated ASCO Phenotyping). Cerebrovasc Dis. 2013;36(1):1-5. https://doi.org/10.1159/000352050
• 16 Kent DM, Thaler DE; RoPE Study Investigators. The Risk of Paradoxical Embolism (RoPE) Study: Developing risk models for application to ongoing randomized trials of percutaneous patent foramen ovale closure for cryptogenic stroke. Trials. 2011 Jul;12:185. https://doi.org/10.1186/1745-6215-12-185
• 17 Kent DM, Ruthazer R, Weimar C, Mas JL, Serena J, Homma S, et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology. 2013 Aug;81(7):619-25. https://doi.org/10.1212/WNL.0b013e3182a08d59
• 18 Morais LA, Sousa L de, Fiarresga A, Martins JD, Timóteo AT, Monteiro AV, et al. RoPE score as a predictor of recurrent ischemic events after percutaneous patent foramen ovale closure. Int Heart J. 2018 Nov 28;59(6):1327-32. https://doi.org/10.1536/ihj.17-489
• 19 Bernd Ringelstein E, Droste DW, Babikian VL, Evans DH, Grosset DG, Kaps M, et al. Consensus on Microembolus Detection by TCD. Stroke. 1998 Mar;29(3):725-9. https://doi.org/10.1161/01.str.29.3.725
• 20 Lao AY, Sharma VK, Tsivgoulis G, Frey JL, Malkoff MD, Navarro JC, et al. Detection of right-to-left shunts: comparison between the International Consensus and Spencer Logarithmic Scale criteria. J Neuroimaging. 2008 Oct;18(4):402-6. https://doi.org/10.1111/j.1552-6569.2007.00218.x
• 21 Thaler DE, Ruthazer R, Weimar C, Mas JL, Serena J, Di Angelantonio E, et al. Recurrent stroke predictors differ in medically treated patients with pathogenic vs other PFOs. Neurology. 2014 Jul;83(3):221-6. https://doi.org/10.1212/WNL.20200430202004300589
• 22 Wessler BS, Kent DM, Thaler DE, Ruthazer R, Lutz JS, Serena J. The RoPE score and right-to-left shunt severity by transcranial Doppler in the CODICIA Study. Cerebrovasc Dis. 2015;40(1-2):52-8. https://doi.org/10.1159/000430998
• 23 Fazio G, Ferro G, Carità P, Lunetta M, Gullotti A, Trapani R, et al. The PFO anatomy evaluation as possible tool to stratify the associated risks and the benefits arising from the closure. Eur J Echocardiogr. 2010 Jul;11(6):488-91. https://doi.org/10.1093/ejechocard/jeq003
• 24 Zetola VF, Lange MC, Scavasine VC, Bazan R, Braga GP, Leite ACCB, et al. Latin American consensus statement for the use of contrast-enhanced transcranial ultrasound as a diagnostic test for detection of right-to-left shunt. Cerebrovasc Dis. 2019;48(3-6):99-108. https://doi.org/10.1159/000503851
• 25 Tuttolomondo A, Pinto A, Salemi G, Di Raimondo D, Di Sciacca R, Fernandez P, et al. Diabetic and non-diabetic subjects with ischemic stroke: differences, subtype distribution and outcome. Nutr Metab Cardiovasc Dis. 2008 Feb;18(2):152-7. https://doi.org/10.1016/j.numecd.2007.02.003
• 26 Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, Longstreth WT Jr, Psaty BM. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology. 2004 Nov;63(10):1868-75. https://doi.org/10.1212/01.wnl.0000144282.42222.da
• 27 Herrington W, Lacey B, Sherlike P, Armitage J, Lewington S. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circ Res. 2016 Feb;118(4):535-46. https://doi.org/10.1161/CIRCRESAHA.115.307611
• 28 Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic stroke of undetermined source: a systematic review and clinical update. Stroke. 2017 Apr;48(4):867-72. https://doi.org/10.1161/STROKEAHA.116.016414
• 29 Ahmad Y, Howard JP, Arnold A, Shin MS, Cook C, Petraco R, et al. Patent foramen ovale closure vs. medical therapy for cryptogenic stroke: a meta-analysis of randomized controlled trials. Eur Heart J. 2018 May;39(18):1638-49. https://doi.org/10.1093/eurheartj/ehy121
• 30 Akobeng AK, Abdelgadir I, Boudjemline Y, Hijazi ZM. Patent foramen ovale (PFO) closure versus medical therapy for prevention of recurrent stroke in patients with prior cryptogenic stroke: A systematic review and meta-analysis of randomized controlled trials. Catheter Cardiovasc Interv. 2018 Jul;92(1):165-73. https://doi.org/10.1002/ccd.27615
• 31 Ntaios G, Papavasileiou V, Sagris D, Makaritsis K, Vemmos K, Steiner T, et al. Closure of patent foramen ovale versus medical therapy in patients with cryptogenic stroke or transient ischemic attack. Stroke. 2018 Feb;49(2):412-8. https://doi.org/10.1161/STROKEAHA.117.020030
• 32 Saqqur M, Dean N, Schebel M, Hill MD, Salam A, Shuaib A, et al. Improved detection of microbubble signals using power m-mode Doppler. Stroke. 2004 Jan;35(1):e14-7. https://doi.org/10.1161/01.STR.0000106771.62928.66
• 33 Lange MC, Zétola VF, Souza AM, Piovesan EJ, Muzzio JA, Germiniani JMB, et al. Transcranial Doppler for patent foramen ovale screening. Arq Neuropsiquiatr. 2008 Dec;66(4):785-9. https://doi.org/10.1590/s0004-282x2008000600001
• 34 Katsanos AH, Psaltopoulou T, Sergentanis TN, Frogoudaki A, Vrettou AR, Ikonomidis I, et al. Transcranial Doppler versus transthoracic echocardiography for the detection of patent foramen ovale in patients with cryptogenic cerebral ischemia: A systematic review and diagnostic test accuracy meta-analysis. Ann Neurol. 2016 Apr;79(4):625-35. https://doi.org/10.1002/ana.24609
• 35 Mahmoud NA, Elgendy IY, Agarwal N, Tobis JM, Mojadidi MK. Identification and Quantification of Patent Foramen Ovale-Mediated Shunts: Echocardiography and Transcranial Doppler. Interv Cardiol Clin. 2017 Oct;6(4):495-504. https://doi.org/10.1016/j.iccl.2017.05.002